Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma
Laure Hirsch, Ronan Flippot, Bernard Escudier, et al.
Drugs (2020) Vol. 80, Iss. 12, pp. 1169-1181
Closed Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma
David A. Braun, Ziad Bakouny, Laure Hirsch, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 4, pp. 199-214
Open Access | Times Cited: 256
Macrophage Polarity and Disease Control
Suguru Kadomoto, Kouji Izumi, Atsushi Mizokami
International Journal of Molecular Sciences (2021) Vol. 23, Iss. 1, pp. 144-144
Open Access | Times Cited: 200
Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
Da‐Liang Ou, Chia-Wei Chen, Chia‐Lang Hsu, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 3, pp. e001657-e001657
Open Access | Times Cited: 100
Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis
Michael Saerens, Nele Brusselaers, Sylvie Rottey, et al.
European Journal of Cancer (2021) Vol. 152, pp. 165-182
Open Access | Times Cited: 86
Loss of Von Hippel–Lindau (VHL) Tumor Suppressor Gene Function: VHL–HIF Pathway and Advances in Treatments for Metastatic Renal Cell Carcinoma (RCC)
Hyunho Kim, Byoung Yong Shim, Seung‐Ju Lee, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 18, pp. 9795-9795
Open Access | Times Cited: 63
Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma
Myung‐Chul Kim, Jin Zeng, Ryan Kolb, et al.
Cancers (2021) Vol. 13, Iss. 22, pp. 5856-5856
Open Access | Times Cited: 59
The Effect of Hypoxia and Hypoxia-Associated Pathways in the Regulation of Antitumor Response: Friends or Foes?
Raefa Abou Khouzam, Rania F. Zaarour, Klaudia Brodaczewska, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 49
Current and emerging therapies for neuroendocrine prostate cancer
Busola R. Alabi, Shiqin Liu, Tanya Stoyanova
Pharmacology & Therapeutics (2022) Vol. 238, pp. 108255-108255
Closed Access | Times Cited: 41
Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment
Junyu Qiu, Zilin Cheng, Zheng Jiang, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5490-5490
Open Access | Times Cited: 13
Understanding and overcoming resistance to immunotherapy in genitourinary cancers
S. Evans, Yash Jani, Caroline S. Jansen, et al.
Cancer Biology & Therapy (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 8
Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives
Mathieu Larroquette, Florent Peyraud, Charlotte Domblides, et al.
Cancer Treatment Reviews (2021) Vol. 97, pp. 102207-102207
Closed Access | Times Cited: 42
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial
Toni K. Choueiri, James Larkin, Sumanta K. Pal, et al.
ESMO Open (2021) Vol. 6, Iss. 3, pp. 100101-100101
Open Access | Times Cited: 42
A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression
Wentao Liu, Dianyun Ren, Wei Xiong, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 30
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial
Kathryn E. Beckermann, Aviva G. Asnis-Alibozek, Michael B. Atkins, et al.
The Oncologist (2024) Vol. 29, Iss. 3, pp. 254-262
Open Access | Times Cited: 6
Targeting VEGF signaling for tumor microenvironment remodeling and metastasis inhibition: Therapeutic strategies and insights
Hanie Mahaki, Sima Nobari, Hamid Tanzadehpanah, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 186, pp. 118023-118023
Closed Access
Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy
Houhui Shi, Kai Li, Yanghong Ni, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 27
Renal cancer: signaling pathways and advances in targeted therapies
Aimin Jiang, Jinxin Li, Ziwei He, et al.
MedComm (2024) Vol. 5, Iss. 8
Open Access | Times Cited: 4
Neutrophil to lymphocyte ratio and tumour burden for treatment efficacy stratification in renal cell carcinoma patients receiving nivolumab plus ipilimumab
Motohiko Oshima, Satoshi Washino, S. Shirotake, et al.
ESMO Real World Data and Digital Oncology (2025) Vol. 7, pp. 100106-100106
Closed Access
Therapeutic efficacy of immune-oncology combination therapy in advanced renal cell carcinoma without prior nephrectomy
Kousuke Ueda, Naoki Ito, Yuya Sakai, et al.
International Journal of Clinical Oncology (2025)
Open Access
Natural small molecule thymoquinone increases the chemosensitivity of glioblastoma to temozolomide through inhibiting Wnt/β-catenin signaling pathway to downregulate MGMT expression: In vitro and in vivo validation
Peiying Bai, Peng Wang, Ting Ren, et al.
Biochemical Pharmacology (2025), pp. 116886-116886
Closed Access
Prognostic Impact of the Maximal Evaluable Lesion Size in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab Combination Therapy
Yoshie Mita, Jun Teishima, Takuto Hara, et al.
International Journal of Urology (2025)
Closed Access
Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations
Roberto Iacovelli, Chiara Ciccarese, Giuseppe Procopio, et al.
Cancer Treatment Reviews (2022) Vol. 105, pp. 102379-102379
Closed Access | Times Cited: 16
Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma
Yohei Sekino, Jun Teishima, Gangning Liang, et al.
International Journal of Urology (2022) Vol. 29, Iss. 12, pp. 1419-1428
Open Access | Times Cited: 16
Neoadjuvant Immune Checkpoint Inhibitors for Resectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Mei Zhao, Shanwen Chen, Conggui Li, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 600-600
Open Access | Times Cited: 9
PDZK1 confers sensitivity to sunitinib in clear cell renal cell carcinoma by suppressing the PDGFR-β pathway
Haibo Wang, Lijie Zhang, Hua Liu, et al.
British Journal of Cancer (2024) Vol. 131, Iss. 2, pp. 347-360
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top